Maze Therapeutics Q2 2026: Wider Loss Offset by Pipeline Progress and Cash Runway into 2029

summarizeSummary

Maze Therapeutics posted a wider Q2 net loss of $44.7M on increased R&D spending, while its $494.9M cash position supports operations into 2029. Key pipeline catalysts are on track, with Phase 2 data for MZE829 expected in late 2026 or early 2027.

check_boxKey Events · Earnings and Guidance · MAZE

• Q2 Net Loss Widens

  Driven by higher R&D expenses for the MZE829 and MZE782 programs, the net loss reached $44.7M ($0.76/share) compared with $33.7M ($0.77/share) in Q2 2025.

• Strong Cash Position

  As of June 30, 2026, cash, cash equivalents and marketable securities totaled $494.9M, which is expected to fund operations into 2029.

• MZE829 Phase 2 Data Timeline

  Enrollment in the HORIZON trial remains on track; updated data on three 10-15 patient cohorts are expected in late 2026 or early 2027.

• MZE782 Phase 2 Initiated in PKU

  The CIPheR trial in PKU has been initiated and is enrolling, with topline data expected in 2027. A Phase 2 trial in CKD is planned for H1 2027.

auto_awesomeAnalysis · MAZE · Life Sciences

A net loss of $44.7 million in Q2 reflects the ramp-up in R&D spending as Maze Therapeutics advances its two lead programs. With $494.9 million in cash, the company has a runway into 2029 — a liquidity position that eliminates near-term financing risk. On the pipeline front, enrollment continues in the Phase 2 HORIZON trial for MZE829, with data expected in late 2026 or early 2027, and the Phase 2 CIPheR trial for MZE782 in PKU has been initiated. These milestones mark the next value-inflection points for this clinical-stage biotech. The extended runway is especially notable given the recent insider selling trend, suggesting the company is well-funded to execute its clinical plans without immediate dilution.